Traws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Rating of “Reduce” by Brokerages

Traws Pharma, Inc. (NASDAQ:TRAW) has received a consensus rating of “Reduce” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $1.00.

A number of equities research analysts recently weighed in on TRAW shares. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Weiss Ratings lowered shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. LADENBURG THALM/SH SH lowered shares of Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Finally, HC Wainwright reaffirmed a “negative” rating and set a $1.00 price target on shares of Traws Pharma in a report on Thursday.

Traws Pharma Stock Performance

TRAW opened at $0.85 on Monday. The company has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $1.68. The firm has a market cap of $8.64 million, a price-to-earnings ratio of -0.50 and a beta of 1.45. Traws Pharma has a twelve month low of $0.64 and a twelve month high of $3.27.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.39. On average, analysts forecast that Traws Pharma will post -1.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Orbimed Advisors Llc acquired 597,729 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was bought at an average cost of $1.67 per share, with a total value of $998,207.43. Following the acquisition, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. The trade was a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.57% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TRAW. State Street Corp acquired a new position in Traws Pharma during the 4th quarter worth $29,000. Two Sigma Investments LP grew its holdings in Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares in the last quarter. XTX Topco Ltd grew its holdings in Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after acquiring an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Traws Pharma during the 4th quarter worth $56,000. Finally, Geode Capital Management LLC grew its holdings in Traws Pharma by 41.9% during the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after acquiring an additional 18,213 shares in the last quarter. 7.95% of the stock is owned by institutional investors and hedge funds.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.